 Home > Active Ingredient News > Antitumor Therapy > Ther Adv Med Oncol: Reveal the 20-year treatment and clinical prognosis of patients with HER2+ advanced breast cancer (PANHER study)

Ther Adv Med Oncol: Reveal the 20-year treatment and clinical prognosis of patients with HER2+ advanced breast cancer (PANHER study)

 Last Update: 2022-01-08
 Source: Internet
 Author: User

Tags

anti estrogen drugs

1 2 3 4

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, scholars from Italy published observational PANHER research results in Therapeutic Advances in Medical Oncology, mainly to evaluate the efficacy and prognosis of anti-HER2 therapy in patients with HER2+ advanced breast cancer (BC)
.

Breast cancer

The PANHER study included 1328 HER2-positive advanced BC patients who received anti-HER2 therapy from June 2000 to July 2020
.

The efficacy endpoints are progression-free survival (PFS) and overall survival (OS)

diagnosis

First-line treatment: 358 patients (26.
9%) with trastuzumab + chemotherapy, 749 patients (56.
4%) with Pertuzumab/trastuzumab/taxane, and 37 patients (2.
8%) with T-DM1 Among the patients, 41 patients (3.
4%) of lapatinib/capecitabine, and 143 patients (10.
7%) of other treatments, such as endocrine therapy + trastuzumab
.

Second-line treatment: 335 cases (41.

The median follow-up time for the overall population was 52 months (95% CI, 48-56)
.

In the first-line treatment, the 2-year PFS rate of 749 patients who received Pertuzumab/trastuzumab/taxane was 50.

807 patients received second-line treatment, the 2-year PFS rate was 20%, and the median PFS was 8 months (95% CI, 7.
1-8.
7)
.

The 2-year PFS rate of patients treated with T-DM1 was 24.

807 patients received second-line treatment, the 2-year PFS rate was 20%, and the median PFS was 8 months (95% CI, 7.

The median PFS of first-line patolizumab was 7 months (95% CI, 2.
1-11.
9) and 7 months (95%) for second-line lapatinib/capecitabine or TDM-1 treatment, respectively CI 5.
1–8.
9) (p = 0.
80)
.

For patients who have not previously been treated with patolizumab, the median PFS of second-line lapatinib/capecitabine or TDM-1 treatment was 8 months (95% CI, 6.

The median PFS of first-line patolizumab was 7 months (95% CI, 2.

The 2-year PFS rate of the third-line treatment was 8.
5%, and the median PFS was 7 months (95% CI, 6.
3-7.
7).
There was no significant difference between different treatment regimens
.

In the overall population, the median OS was 60 months (95% CI, 55 65), the 3-year OS rate was 68.
4%, and the 5-year OS rate was 49.
7%
.

In 1328 patients, after diagnosis of metastatic disease, the 3-year OS rate, 5-year OS rate and median OS rate of Pertuzumab/Trastuzumab/Taxane treatment after diagnosis of metastatic disease were 71.

In the overall population, the median OS was 60 months (95% CI, 55 65), the 3-year OS rate was 68.

Overall, among the 807 patients who received second-line treatment, the median OS from the second-line was 28 months (95% CI, 24.
8 31.
1), the 3-year OS rate was 41.
0%, and the 5-year OS rate was 24.
8%
.
Among the 749 patients who received first-line pembrolizumab treatment, those who received second-line T-DM1 treatment (N: 259) had a 3-year OS rate of 63.
6% and a 5-year OS rate of 39.
5%, from the diagnosis to metastatic disease The initial median OS was 48 months (95% CI, 42 54)
.
In the second-line patients receiving lapatinib/capecitabine, the 3-year OS rate was 51.
8%, the 5-year OS rate was 32.
2%, and the median OS was 41 months (95% CI, 28 54) (p = 0.
45) )
.
Overall, among the 807 patients who received second-line treatment, the median OS from the second-line was 28 months (95% CI, 24.
8 31.
1), the 3-year OS rate was 41.
0%, and the 5-year OS rate was 24.
8%
.
Among the 749 patients who received first-line pembrolizumab treatment, those who received second-line T-DM1 treatment (N: 259) had a 3-year OS rate of 63.
6% and a 5-year OS rate of 39.
5%, from the diagnosis to metastatic disease The initial median OS was 48 months (95% CI, 42 54)
.
In the second-line patients receiving lapatinib/capecitabine, the 3-year OS rate was 51.
8%, the 5-year OS rate was 32.
2%, and the median OS was 41 months (95% CI, 28 54) (p = 0.
45) )
.

When OS was diagnosed with metastatic disease, TDM-1 was the second-line treatment.
The 3-year OS rate of patients who had not been treated with Pertuzumab was 78%, and the 5-year OS rate was 55.
4%.
From the diagnosis of metastatic disease The initial median OS was 72 months (95% CI, 44-100), which significantly improved the prognosis of patients compared with previous treatment with patozumab (p = 0.
003)
.
When OS was diagnosed with metastatic disease, TDM-1 was the second-line treatment.
The 3-year OS rate of patients who had not been treated with Pertuzumab was 78%, and the 5-year OS rate was 55.
4%.
From the diagnosis of metastatic disease The initial median OS was 72 months (95% CI, 44-100), which significantly improved the prognosis of patients compared with previous treatment with patozumab (p = 0.
003)
.

When OS starts from second-line treatment, TDM-1 is second-line treatment.
The 3-year OS rate of patients who have not been treated with Pertuzumab in the past was 58.
9%, and the 5-year OS rate was 38.
5%, the median from the diagnosis of metastatic disease OS was 45 months (95% CI, 36–54); the 3-year OS rate of patients treated with Pertuzumab was 32.
2%, and the 5-year OS rate was 24.
4%, the median from the diagnosis of metastatic disease OS was 24 months (95% CI, 19-29) (p = 0.
002)
.
When OS starts from second-line treatment, TDM-1 is second-line treatment.
The 3-year OS rate of patients who have not been treated with Pertuzumab in the past was 58.
9%, and the 5-year OS rate was 38.
5%, the median from the diagnosis of metastatic disease OS was 45 months (95% CI, 36–54); the 3-year OS rate of patients treated with Pertuzumab was 32.
2%, and the 5-year OS rate was 24.
4%, the median from the diagnosis of metastatic disease OS was 24 months (95% CI, 19-29) (p = 0.
002)
.

In summary, studies have shown that compared with patients who were not treated with first-line patolizumab, the efficacy of second-line use of TDM-1 after treatment with patolizumab in the past has been reduced
.

Studies have shown that, compared with patients who were not treated with first-line patolizumab, the efficacy of second-line TDM-1 after the previous treatment with patolizumab was reduced
.
Studies have shown that, compared with patients who were not treated with first-line patolizumab, the efficacy of second-line TDM-1 after the previous treatment with patolizumab is reduced
.

Original source:

Laura Pizzuti, Eriseld Krasniqi, Isabella Sperduti,et al.
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting.
Ther Adv Med Oncol.
2021, Vol .
13: 1 -18.
DOI: 10.
1177/17588359211059873.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.